NIH R01 · 2024
Novel gene delivery to modulate the tumor microenvironment and antigen-specific antitumor immunity
Abstract Technological advancements have yielded novel drug targets and improved cancer detection, but transformative innovations in treatment modalities are lacking. Leveraging our team's expertise in gene therapy, breast cancer, cancer immunology, and breast cancer animal and patient-derived xenograft models, we propose to use recombinant adenovirus with a higher tumor-specific expression of herpes simplex virus-thymidine kinase (HSV-TK), which is a suicide gene that causes tumor cell death. We will combine HSV-TK with our immune checkpoint antibody (i.e. HMR-101) that will specifically target tumor cells, release tumor antigens and change the tumor microenvironment to be more favorable…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.